Cannabis Stocks Plummet By Up To 16% On DEA Rescheduling Delay: Could This Be The Buying Opportunity Of 2024?
Cannabis Stocks Plummet By Up To 16% On DEA Rescheduling Delay: Could This Be The Buying Opportunity Of 2024?
大麻股票因DEA延迟重新分级下跌高达16%：这可能是2024年的购买机会吗？
The U.S. Drug Enforcement Administration (DEA) announced a delay on Monday in its final ruling on cannabis rescheduling until after the November presidential election. The decision, which has created uncertainty in the market, pits Vice President Kamala Harris, a cannabis reform advocate, against former President Donald Trump, whose vice-presidential pick is opposed to legalization.
美国缉毒局（DEA）宣布延迟对大麻重新分类的最终裁决，直到11月总统选举结束后。该决定在市场上造成了不确定性，让大麻改革倡导者、副总统卡玛拉·哈里斯与前总统特朗普的副总统候选人对立，后者反对合法化。
Market Responds With Sharp Declines
市场出现急剧下跌
According to Benzinga Pro, the market's response was immediate and pronounced. The AdvisorShares Pure US Cannabis ETF (NYSE:MSOS) dropped over 10% in early trading, while individual cannabis stocks experienced significant declines.
根据Benzinga Pro的报道，市场立即做出了明显的回应。AdvisorShares Pure US Cannabis ETF（纽交所:MSOS）在早盘交易中下跌超过10%，而个别大麻股票也出现了显著下跌。
Amid the market downturn some of the...
在市场下行中，...
登录免费看全文
登录/注册